Loading clinical trials...
Loading clinical trials...
A Prospective Non-interventional Study to Evaluate the Effectiveness and Safety of Inavolisib in Patients With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer (reaINAVO)
Conditions
Interventions
Inavolisib
Palbociclib
+1 more
Locations
17
China
Gansu Provincial Maternal and Child Health Hospital (Gansu Provincial Hospital of Traditional Chinese Medicine)
Lanzhou, Gansu, China
Wenzhou Medical University Affiliated Second Hospital
Wenzhou, Zhejiang, China
Peking University First Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
Chengdu, China
Chongqing Cancer Hospital
Chongqing, China
Start Date
January 21, 2026
Primary Completion Date
December 31, 2028
Completion Date
September 9, 2029
Last Updated
April 20, 2026
NCT05660083
NCT07354022
NCT02422641
NCT06625775
NCT06649331
NCT07203729
Reference Study ID Number: ML46361 https://forpatients.roche.com/
CONTACT
888-662-6728global-roche-genentech-trials@gene.comLead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions